Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Ovarian Epithelial
/ drug therapy
Cohort Studies
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Staging
Organoplatinum Compounds
/ administration & dosage
Ovarian Neoplasms
/ drug therapy
Progression-Free Survival
Retrospective Studies
Survival Rate
Treatment Outcome
Young Adult
Epithelial ovarian carcinoma
Platinum resistance
Very young woman
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
15
06
2020
accepted:
28
09
2020
pubmed:
17
10
2020
medline:
17
7
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
In young women, EOC is a rare disease with an uncertain genetic and biological substrate. We report a long follow-up of EOC patients treated at Gustave Roussy between 1990 and 2009. We matched young patients aged ≤30 years to randomly selected older patients aged ≥40 years according to known prognostic factors (i.e. FIGO stage, histology and surgical residual disease) and the date of diagnosis with a threshold at the year 2000 to balance the treatment procedures. EOC was diagnosed in 68 patients aged ≤30 years matched with 111 patients aged ≥40 years. Low-grade (LG) (i.e. serous and endometrioid) (52%, n = 35) and mucinous (i.e. 23%, n = 16 infiltrative and 12% n = 8 expansile) tumors are prevalent. High-grade (HG) tumors are rare (7%, n = 5). Early stage diseases (53%, n = 36 FIGO I/II) are predominant. Response to platinum based chemotherapy is observed to be inferior in young patients as compared to matched older patients (ORR, 29 vs 84% p = 0.0002). For HG tumors the PFS is of 0% at 5 and 10 years in younger as compared to 30% in older patients. No difference in PFS (median 4.9 vs 9.8 ms, p = 0.58) and OS (not reached vs 15.3 ms, p = 0.47) is found overall among younger and older patients respectively. The median follow-up was 72 months (range, 11-288 months). No genetic abnormalities were found. Young EOC patients are most often diagnosed at an early FIGO stage with LG serous or mucinous histology. Tumors are significantly more resistant to platinum-based chemotherapy in younger patients.
Identifiants
pubmed: 33059915
pii: S0090-8258(20)33960-3
doi: 10.1016/j.ygyno.2020.09.050
pii:
doi:
Substances chimiques
Organoplatinum Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-82Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. Pautier reports support from Roche, Astra Zeneca, non-financial support from MSD, Clovis, GSK, outside the submitted work. Dr. Leary reports support from Tesaro, Clovis, Astra Zeneca, MSD, Merck Serono, Seattle Genetics, Gridstone, Biocad, Ability, Gamamabs and grants from Merus, Gamamabs, Sanofi, Inivata. Drs Michels, Genestie, Dunant, Caron, Colomba, Pommeret, Rey, Gouy, Duvillard, Le Teuff, Savoye, Lhommé, Morice report no conflict of interest. All authors contributed equally to this practice statement.